Tempo Scan Pacific Tbk

tspc

Overview

TSPC Overview

PT Tempo Scan Pacific Tbk is an Indonesia-based company engaged in the industry of pharmaceuticals, consumer products and cosmetics. The Company’s segments include Pharmaceuticals, Consumer Products and Cosmetics, and Distribution Services. The Pharmaceuticals segment conducts marketing of consumer health products consisting of over the counter; vitamin, mineral and supplement (VMS) and beverage products; nutritional products and herbal products; and prescription medicine products. The Consumer Products and Cosmetics segment markets and distributes own branded products as well as licensed cosmetics products. The Distribution Services segment distributes products to customers. The segment serves customers from various sales branches throughout Indonesia, covering pharma, modern trade, and general trade channels. It also markets and distributes its products overseas through its international business units. Its business network covers about 220 locations that consist of 47 branches.

51015ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: TSPC

Main
Market Cap.
IDR 9.09Trillion

~$578.50M USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

TSPC Valuation Metrics

1,950

IDR

Closing Price on 2024-04-05

Price to Equity

6.43

P/E

At 6.43x P/E TTM, TSPC.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Price to Book

1.18

P/B

At 1.18x P/B TTM, TSPC.JK is trading in line with its peers in the Pharmaceuticals & Health Care Research sector.

Price to Sales

0.70

P/S

At 0.70x P/S TTM, TSPC.JK is trading in line with its peers in the Pharmaceuticals & Health Care Research sector.

Valuing Tempo Scan Pacific Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing Tempo Scan Pacific Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
10.15x
Price/Forward Earnings
-
Enterprise Value/Revenue
0.50x
Enterprise Value/EBITDA
2.94x
PEG Ratio
0.11x

Analyst Ratings

No analyst ratings available yet.

Last closing: IDR1,9502024-04-05
IDR 3,951.64

Considerably Higher Intrinsic Value: Analyst's intrinsic value is of TSPC is IDR3,952, which is 104% higher than TSPC's last closing price of IDR1,950 (as of 2024-04-05).

Valuation Recap of TSPC stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 6.43x is below the ID market average of 8.22x and is trading at a discount to peers in the Pharmaceuticals & Health Care Research sector (8.87x). ●●
Max 3
High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 1.18x is similar to the peers average of 1.29x in the Pharmaceuticals & Health Care Research sector.
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 0.70x is similar to the peers average of 0.80x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of TSPC's valuation relative to its current sales and future earnings growth.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. TSPC's P/CF ratio of 10.15x is considered a relatively high ratio by analysts.
Max 2
Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. TSPC's EV/R ratio of 0.50x is considered extremely underpriced by the market The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.40x. ●●●
Max 3
Medium
Considerably Higher Intrinsic Value: Analyst's intrinsic value is of TSPC is IDR 3,951.64, which is 104% higher than TSPC's last closing price of IDR 1,950.00.●●●
Max 3

Peers

TSPC Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.19.03T8.52T 5.54T 0.48T 39.485.15
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk9.09T11.31T 12.93T 1.41T 6.431.18
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
OMEDPT Jayamas Medica Industri Tbk5.33T2.46T 1.63T 0.22T 23.782.50
Competitiveness Recap of TSPC stock
WeightNotesScore
High
At a market cap of IDR 9,089.65 billion, TSPC.JK ranks 8 in Market Cap out of 10 companies in the Healthcare sector.
Max 2
High
At a PE of 6.43, TSPC.JK ranks 9 out of 10 companies in the Healthcare sector for P/E value. The average PE is -17.68 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of 6.43, TSPC.JK is trading at a lower PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 8.87). A lower P/E value presents a potential value opportunity, but it might also indicate that the company is facing headwinds in its business.
Max 2
Medium
At a revenue of IDR 12.93 trillion, TSPC.JK ranks 2 in Revenue out of 10 companies in the Healthcare sector.●●
Max 2
Medium
At a profit of IDR 1.41 trillion, TSPC.JK ranks 2 in Profit out of 10 companies in the Healthcare sector.●●
Max 2

Future

Future Growth of TSPC

Growth Forecasts

No data available

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are shrinking at a projected rate of -1.18% against the IDX average of +12.0%.

Pharmaceuticals & Health Care Research sector overview
No data is available for TSPC at the moment.
Future growth prospect of TSPC
WeightNotesScore
High
TSPC's projected growth rate of -1.18% is below the ID market average of 11.98%.●●●
Max 3
High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 11.14% in 2024. This number is higher than the previous year 2023's growth rate of 2.48%. This bodes well for TSPC's revenue growth prospects in the next 2 years. ●●
Max 3
Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 2.56% in 2024. This number is higher than the previous year 2023's EPS growth of -8.71%. false
Max 3
Medium
TSPC and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 16.30% in 2024 while revenue growth is projected to increase by 17.10%. These macroeconomic trends will likely be a tailwind for TSPC's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

I Made Dharma Wijaya15.2 years

Vice President Director

Diana Wirawan15.4 years
Linda Lukitasari
Director
Shania
Director
Rorita Lim
Director
Josep Ismanto
Director
Lie Yung Yung
Director
Aviaska Diah Respati H
Director
NamePositionShares%
Aviaska Diah Respati HDirector780,0000.02
Diana WirawanVice President Director1,045,5000.02
Hartaty Susanto Commissioner499,500< 0.01
I Made Dharma WijayaPresident Director454,000< 0.01
Josep IsmantoDirector314,800< 0.01
Lie Yung YungDirector314,000< 0.01
Linda LukitasariDirector410,000< 0.01
Liza Prasodjo Director679,0000.02
Rorita LimDirector404,000< 0.01
ShaniaDirector479,000< 0.01
Expressed in millions IDR, unless otherwise stated

Ownership

TSPC Ownership

Others
12.34%
Insiders
86.65%
Institutions
1.01%
NameNumber of SharesOwnership (%)Value
Pt Bogamulia Nagadi3,883,754,71886.127,573.32B
Public (Scripless)604,262,68213.41,178.31B
Public (Scrip)16,467,1000.3532.11B
Liza Prasodjo 679,0000.021.32B
Diana Wirawan1,045,5000.022.04B
Aviaska Diah Respati H780,0000.021.52B
Rorita Lim404,0000.010.79B
Shania479,0000.010.93B
Hartaty Susanto 499,5000.010.97B
I Made Dharma Wijaya454,0000.010.89B
Josep Ismanto314,8000.010.61B
Lie Yung Yung314,0000.010.61B
Linda Lukitasari410,0000.010.80B

Largest Institutional Buy

Acadian Asset Management LLC
Bought 31-01-2024
+397,500 shares
Dimensional Fund Advisors
Bought 31-01-2024
+89,600 shares

Largest Institutional Sell

FIL Fund Management Limited
Sold 31-01-2024
-17,067,315 shares
FIL Investments (Japan) Limited
Sold 31-01-2024
-16,017,500 shares
Fidelity Investments Canada ULC
Sold 31-01-2024
-4,428,541 shares

Institutional Transactions

Tracking institutional transactions buying / selling of TSPC stock